Across the recent three months, 10 analysts have shared their insights on Viridian Therapeutics (NASDAQ:VRDN), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Viridian Therapeutics, revealing an average target of $37.2, a high estimate of $47.00, and a low estimate of $27.00. Observing a downward trend, the current average is 0.05% lower than the prior average price target of $37.22.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in...
Login or create a forever free account to read this news
Sign up/Log in
